ARROWHEAD PHARMACEUTICALS, INC. — Director's Dealing 2021

Jan 13, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
CIK: 0000879407
Period of Report: 2021-01-11

Reporting Person: Myszkowski Kenneth Allen (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-11	Common Stock	S	11597	$81.02	Disposed	445446	Direct
2021-01-12	Common Stock	S	1441	$81.00	Disposed	444005	Direct

Footnotes

F1: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.08, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.